Top Markets
#1 Cortex Cortex +33.23%
#2 DexNet DexNet +23.20%
#3 龙虾 (Lobster) 龙虾 (Lobster) +20.86%
#4 wojak wojak +17.61%
#5 Akedo Akedo +15.36%
#6 Pons Pons +14.76%
#7 OpenEden OpenEden +11.18%
#8 EXOD EXOD +9.04%
#9 Official Trump Official Trump +8.63%
#10 The Black Bull The Black Bull +8.63%
Coin of the day
Cortex Cortex
Settings
Language
ENGLISH
Currency
USD
Theme
Chinook Therapeutics, Inc. Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc.

KDNY
Rank in Stocks #7144
Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical... Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials. This drug aims to treat IgA nephropathy and various other glomerular diseases characterized by proteinuria. Beyond its lead program, Chinook's investigational pipeline includes BION-1301, an anti-APRIL monoclonal antibody, which is presently being evaluated in a Phase I/II study for IgA nephropathy. Another promising candidate is CHK-336, an oral small molecule designed to inhibit LDHA, intended for patients with primary hyperoxaluria. The firm also maintains active research initiatives exploring solutions for other uncommon and severe chronic kidney ailments. Chinook Therapeutics, Inc. is based in Seattle, Washington.
Share Price
$40.39
Last synced: 2023-08-18
Market Cap
$1.70B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Chinook Therapeutics, Inc. (KDNY)

Category

Healthcare
Revenue for Chinook Therapeutics, Inc. (KDNY)
Revenue in Aug 2026 TTM: 0
According to Chinook Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Chinook Therapeutics, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH